Yakup Ergün

Yakup Ergün: PRODIGE 23: Long-term results

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared insight about a study by Thierry Conroy et al. on X:

“PRODIGE 23: Long-term results

Neoadj FOLFIRINOX vs SoC (CRT)

  • 7y-DFS: 67.6 vs 62.5%
  • 7y-MFS:79.2 vs 72.3%
  • 7y-OS:81.9 vs76.1%

Induction chemotherapy with mFOLFIRINOX improves OS in LARC patients.”

Yakup Ergün: PRODIGE 23: Long-term results

Read the article.
Source: Yakup Ergün/X

7-year disease-free survival 7-year metastasis-free survival 7-year overall survival Antalya City Hospital cancer Cancer research CRT induction chemotherapy LARC locally advanced rectal cancer long-term results medical oncology mFOLFIRINOX neoadjuvant FOLFIRINOX OncoDaily Oncology PRODIGE 23 Standard of Care Thierry Conroy Yakup Ergün